Fulgent Genetics, Inc. was incorporated in Delaware on May 13, 2016. The company is a technology-based company with a mature clinical diagnostic business and treatment development business. The company's clinical diagnostic business provides molecular diagnostic testing services, comprehensive genetic testing and high-quality anatomical pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. The company's therapeutic development business focuses on the development of drug candidates for the treatment of a variety of cancers using novel nano-encapsulation and targeted therapy platforms designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company's goal is to transform from a genomic diagnostic business to a fully integrated precision medicine company.